PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibroste ...

Palisade Bio, Inc. (NASDAQ: PALI) shares barely cleared breakeven Wednesday. The company, a clinical-stage biopharmaceutical concern developing next-generation, once-daily, oral PDE4 inhibitor ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and ...

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and ...

Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...

Terminal is unlocked at the end of Escape From Tarkov's main story. Once you've completed all the prerequisite quests, you can transition to Terminal from the Shoreline map. The transition point to ...

1 Department of Surgery, School of Medicine, Walailak University, Nakhon Si Thammarat, Thailand 2 Department of Internal Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat, ...

"The consistency of treatment effect across disease locations is important, as ileal Crohn's disease (CD) is highly correlated with negative long-term outcomes and the fact that the terminal ileum ...

INCHEON, South Korea, Nov. 26, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that a post-hoc analysis of the LIBERTY-CD study, which showed that the efficacy of ZYMFENTRA® (infliximab-dyyb) is ...